1,3-Dibenzyl-5-Fluorouracil Prevents Ovariectomy-Induced Bone Loss by Suppressing Osteoclast Differentiation

키워드

참고문헌 (49)

1. Amarasekara DS, "Regulation of osteoblast differentiation by cytokine networks", Int J Mol Sci, 22, pp.2851~ (2021)
2. Dulshara Sachini Amarasekara, "Regulation of Osteoclast Differentiation by Cytokine Networks", Immune Network, 18(1), pp.1~18 (2018), 대한면역학회[DOI]
3. Walsh MC, "Osteoimmunology : interplay between the immune system and bone metabolism", Annu Rev Immunol, 24, pp.33~63 (2006)
4. Amarasekara DS, "Bone loss triggered by the cytokine network in inflammatory autoimmune diseases", J Immunol Res, 2015, pp.832127~ (2015)
5. Darnay BG, "TRAFs in RANK signaling", Adv Exp Med Biol, 597, pp.152~159 (2007)
6. Kim N, "A novel member of the leukocyte receptor complex regulates osteoclast differentiation", J Exp Med, 195, pp.201~209 (2002)
7. Lee SH, "v-ATPase V0subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation", Nat Med, 12, pp.1403~1409 (2006)
8. Rho J, "Gene expression profiling of osteoclast differentiation by combined suppression subtractive hybridization(SSH)and cDNA microarray analysis", DNA Cell Biol, 21, pp.541~549 (2002)
9. Ji MX, "Primary osteoporosis in postmenopausal women", Chronic Dis Transl Med, 1, pp.9~13 (2015)
10. Riggs BL, "The mechanisms of estrogen regulation of bone resorption", J Clin Invest, 106, pp.1203~1204 (2000)
11. Pfeilschifter J, "Hormone replacement and selective estrogen receptor modulators(SERMS)in the prevention and treatment of postmenopausal osteoporosis", Orthopade, 30, pp.462~472 (2001)
12. Migliaccio S, "The differential effects of bisphosphonates, SERMS(selective estrogen receptor modulators), and parathyroid hormone on bone remodeling in osteoporosis", Clin Interv Aging, 2, pp.55~64 (2007)
13. Anastasilakis AD, "Therapy of endocrine disease : denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis", Eur J Endocrinol, 179, pp.R31~R45 (2018)
14. Khosla S, "Benefits and risks of bisphosphonate therapy for osteoporosis", J Clin Endocrinol Metab, 97, pp.2272~2282 (2012)
15. Liberman UA, "Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis", N Engl J Med, 333, pp.1437~1443 (1995)
16. Ma S, "Long-term effects of bisphosphonate therapy : perforations, microcracks and mechanical properties", Sci Rep, 7, pp.43399~ (2017)
17. Zhang N, "Pros and cons of denosumab treatment for osteoporosis and implication for RANKL aptamer therapy", Front Cell Dev Biol, 8, pp.325~ (2020)
18. Chandran T, "Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis : a systematic review", Singapore Med J, 60, pp.364~378 (2019)
19. Black DM, "Effects of continuing or stopping alendronate after 5 years of treatment : the Fracture Intervention Trial Long-term Extension(FLEX) : a randomized trial", JAMA, 296, pp.2927~2938 (2006)
20. Bone HG, "10 years of denosumab treatment in postmenopausal women with osteoporosis : results from the phase 3 randomised FREEDOM trial and open-label extension", Lancet Diabetes Endocrinol, 5, pp.513~523 (2017)
21. Lorentzon M, "Treating osteoporosis to prevent fractures : current concepts and future developments", J Intern Med, 285, pp.381~394 (2019)
22. Bone HG, "Effects of denosumab on bone mineral density and bone turnover in postmenopausal women", J Clin Endocrinol Metab, 93, pp.2149~2157 (2008)
23. Kim B, "Osteoporosis therapies and their mechanisms of action(review)", Exp Ther Med, 22, pp.1379~ (2021)
24. Wu J, "Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis : a meta-analysis", J Orthop Surg, 13, pp.194~ (2018)
25. Shin B, "Secretion of a truncated osteopetrosis-associated transmembrane protein 1(OSTM1)mutant inhibits osteoclastogenesis through down-regulation of the B lymphocyte-induced maturation protein 1(BLIMP1)-nuclear factor of activated T cells c1(NFATc1)axis", J Biol Chem, 289, pp.35868~35881 (2014)
26. Yu J, "Interaction of tumor necrosis factor receptor-associated factor 6(TRAF6)and Vav3 in the receptor activator of nuclear factor κB(RANK)signaling complex enhances osteoclastogenesis", J Biol Chem, 291, pp.20643~20660 (2016)
27. Ha H, "Water extract of Spatholobus suberectus inhibits osteoclast differentiation and bone resorption", BMC Complement Altern Med, 13, pp.112~ (2013)
28. Yu J, "Pax5 negatively regulates osteoclastogenesis through downregulation of Blimp1", Int J Mol Sci, 22, pp.2097~ (2021)
29. Kim T, "ATP6v0d2 deficiency increases bone mass, but does not influence ovariectomy-induced bone loss", Biochem Biophys Res Commun, 403, pp.73~78 (2010)
30. Yamamoto M, "TNF receptor-associated factor 6(TRAF6)plays crucial roles in multiple biological systems through polyubiquitination-mediated NF-κB activation", Proc Jpn Acad Ser B Phys Biol Sci, 97, pp.145~160 (2021)
31. Iotsova V, "Osteopetrosis in mice lacking NF-κB1 and NF-κB2", Nat Med, 3, pp.1285~1289 (1997)
32. Xing L, "NF-κB p50 and p52expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK-and cytokine-mediated osteoclastogenesis", J Bone Miner Res, 17, pp.1200~1210 (2002)
33. Negishi-Koga T, "Ca2+-NFATc1 signaling is an essential axis of osteoclast differentiation", Immunol Rev, 231, pp.241~256 (2009)
34. Liu T, "NF-κB signaling in inflammation", Signal Transduct Target Ther, 2, pp.17023~ (2017)
35. Lawrence T, "IKKα limits macrophage NF-κB activation and contributes to the resolution of inflammation", Nature, 434, pp.1138~1143 (2005)
36. Zhong H, "Phosphorylation of NF-κB p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP", p300, 1998, pp.1, 661~671
37. Asagiri M, "The molecular understanding of osteoclast differentiation", Bone, 40, pp.251~264 (2007)
38. Kim H, "Selective inhibition of RANK blocks osteoclast maturation and function and prevents bone loss in mice", J Clin Invest, 119, pp.813~825 (2009)
39. Mansky KC, "Microphthalmia transcription factor is a target of the p38MAPK pathway in response to receptor activator of NF-κB ligand signaling", J Biol Chem, 277, pp.11077~11083 (2002)
40. Matsumoto M, "Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-κB ligand(RANKL)", J Biol Chem, 275, pp.31155~31161 (2000)
41. David JP, "JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and-independent mechanisms", J Cell Sci, 115, pp.4317~4325 (2002)
42. Lee K, "Roles of mitogen-activated protein kinases in osteoclast biology", Int J Mol Sci, 19, pp.3004~ (2018)
43. Sundaram K, "RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation", Exp Cell Res, 313, pp.168~178 (2007)
44. Wagner EF, "Signalling in osteoclasts and the role of Fos", AP1 proteins, 2003, pp.62(Suppl 2), ii83~ii85
45. Meissner JD, "Extracellular signalregulated kinase 1", 2-mediated phosphorylation of p300 enhances myosin heavy chain I, Nucleic Acids Res, pp.2011, 39[DOI]
46. Nakamura H, "Role of osteoclast extracellular signal-regulated kinase(ERK)in cell survival and maintenance of cell polarity", J Bone Miner Res, 18, pp.1198~1205 (2003)
47. He Y, "Erk1 positively regulates osteoclast differentiation and bone resorptive activity", PLoS One, 6, pp.e24780~ (2011)
48. Bradley EW, "Pathway crosstalk between Ras", Raf and PI3K in promotion of M-CSF-induced MEK, J Cell Biochem, pp.2008, 104[DOI]
49. Ross FP, "M-CSF, c-Fms, and signaling in osteoclasts and their precursors", Ann N Y Acad Sci, 1068, pp.110~116 (2006)

관련 논문AI추천